Narcolepsy: 2018 Pipeline Insights - Detailed Analysis of 20+ Products Along With 15+ Companies Involved - ResearchAndMarkets.com

DUBLIN--()--The "Narcolepsy - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of the present scenario and growth prospects across Narcolepsy.

A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 20+ products along with 15+ companies involved.

Products Covered by Phase

  • Phase III, Phase II, Phase I and IND
  • Pre-clinical & Discovery
  • Inactive (Dormant and Discontinued)

Scope of the Report

  • Provides an overview of therapeutic pipeline activity for Narcolepsy across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Narcolepsy therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Narcolepsy

Companies Mentioned

  • Arena Pharmaceuticals
  • Avadel Pharmaceuticals
  • Balance Therapeutics
  • Evotec AG
  • GlaxoSmithKline
  • Heptares Therapeutics
  • Jazz Pharmaceuticals
  • Johnson & Johnson
  • NLS Pharma
  • Ono Pharmaceutical
  • OptiNose
  • Pfizer
  • Reset Therapeutics
  • Roche
  • Sanofi
  • Seelos Therapeutics
  • Taisho Pharmaceutical
  • Takeda
  • Theranexus

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/d7nfb9/narcolepsy_2018?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs